Paper Details

  1. Home
  2. Paper Details

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome.

Author: BlaydornLisa, CaroIvor, DownhourMolly, JamesonGayle, TibesRaoul, Von HoffDaniel D, WeissGlen J, WhiteErica

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Vismodegib is a medication used to treat advanced basal cell carcinoma (BCC). This report describes the experience of two patients who have been treated with vismodegib for over two years without experiencing significant side effects.
Paper Details　
Original Abstract of the Article :
Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211514/

データ提供：米国国立医学図書館（NLM）

Vismodegib: A Long-Term Solution for Advanced BCC

Basal cell carcinoma (BCC) is a common type of skin cancer. This research reports on the long-term safety, tolerability, and efficacy of vismodegib, a SMO antagonist, in treating advanced BCC, specifically in patients with basal cell nevus syndrome.

A Promising Treatment for a Challenging Cancer

The study followed two patients with advanced BCC who received continuous daily treatment with vismodegib for over 2.75 years. Both patients experienced no new BCC development and showed no significant side effects. This suggests that vismodegib may be a safe and effective long-term treatment option for advanced BCC.

Hope for a Long-Term Solution

This case report demonstrates the potential of vismodegib as a long-term treatment for advanced BCC, providing hope for patients seeking durable control of this challenging condition. However, further research is needed to confirm the long-term safety and efficacy of vismodegib in a larger population.

Dr.Camel's Conclusion

This case report offers promising evidence for the long-term safety and efficacy of vismodegib in treating advanced BCC. While further research is needed to confirm these findings, this study provides hope for patients seeking durable control of this challenging condition. The long-term tolerability of vismodegib underscores its potential as a valuable tool in the management of advanced BCC.

Date :
  1. Date Completed 2014-11-11
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

25386306

DOI: Digital Object Identifier

PMC4211514

Related Literature

Article Analysis
・Side Effects of vismodegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.